GigaGen Awarded U.S. BARDA Contract Valued Up To $135.2M To Develop Recombinant Polyclonal Antibody Therapies For Botulinum Neurotoxins And An Additional Biothreat
Portfolio Pulse from Benzinga Newsdesk
GigaGen, a subsidiary of Grifols, has been awarded a BARDA contract worth up to $135.2 million to develop recombinant polyclonal antibody therapies for botulinum neurotoxins and another biothreat. The contract includes an initial $19.6 million commitment and supports drug manufacturing and phase 1 trials.
October 03, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Grifols' subsidiary, GigaGen, has secured a significant BARDA contract worth up to $135.2 million, enhancing its innovation strategy in antibody drug development. This contract supports the development of therapies for botulinum neurotoxins and another biothreat.
The BARDA contract is a substantial financial commitment that aligns with Grifols' innovation strategy, potentially boosting its reputation and financial outlook. The initial $19.6 million funding and the potential total of $135.2 million over six years indicate strong support for GigaGen's projects, likely leading to positive investor sentiment.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80